Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

2(40.0%)

Phase 1

1(20.0%)

5Total

N/A(2)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00493883Phase 1Completed

Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

Role: lead

NCT01760694Not ApplicableTerminated

Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer

Role: lead

NCT01401309Completed

PET Respiratory Gating to Detect Hepatic Metastasis in Patients With Colon Cancer

Role: lead

NCT01152879Completed

Home Parenteral Nutrition in Cancer Patients

Role: lead

NCT00379665Phase 2Completed

Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy

Role: lead

NCT00519545Not ApplicableCompleted

Prayer as a Possible Adjuvant Treatment for Breast Cancer

Role: lead

NCT00385021Phase 2Terminated

ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer

Role: lead

All 7 trials loaded